Difference between revisions of "Maple Syrup Urine Disease"

From Bioinformatikpedia
m (→‎Genetics of pathognesis)
m (→‎Tasks)
 
(30 intermediate revisions by 2 users not shown)
Line 1: Line 1:
−
[[Image:MSUD_BCKDC_E1.jpg|frame| Crystal structure of the human mitochondrial branched-chain alpha-ketoacid dehydrogenase, subunit E1 (source: http://www.pdb.org/)]]
 +
[[Image:MSUD_BCKDC_E1subunit.jpg|thumb|500px| Crystal structure of the human mitochondrial branched-chain α-ketoacid dehydrogenase, subunit E1 (source: http://www.pdb.org/, pdb-id 1U5B)]]
   
 
== Summary ==
  
== Summary ==
−
Maple syrup urine disease (MSUD) is a disorder of the branched chain amino acid ([http://en.wikipedia.org/wiki/Branched-chain_amino_acid BCAA]) catabolism. Due to a deficiency in the branched chain alpha-keto acid dehydrogenase complex ([http://en.wikipedia.org/wiki/Branched-chain_alpha-keto_acid_dehydrogenase_complex BCKDC]) the degradation of leucine, isoleucine and valine is impaired so that these amino acids and the corresponding alpha-keto acids accumulate. Affected infants suffer from mental and physical retardation. MSUD has an autosomal recessive heredity.
 +
Maple syrup urine disease (MSUD) is a disorder of the branched chain amino acid (BCAA) catabolism. Due to a deficiency in the branched chain α-keto acid dehydrogenase complex (BCKDC) the degradation of leucine, isoleucine and valine is impaired so that these amino acids and the corresponding α-keto acids accumulate. Affected infants suffer from mental and physical retardation. MSUD has an autosomal recessive heredity.
  +
  +
The slides of the introductory talk can be found here: [[Media:MSUD_presentation.pdf|MSUD presentation]]
   
 
== Phenotype ==
  
== Phenotype ==
Line 8: Line 10:
   
 
The name of the disease comes from the sweet smell of newbornes urine that resembles maple syrup. The compound sotolone, a metabolite of leucine, is responsible for this smell.
  
The name of the disease comes from the sweet smell of newbornes urine that resembles maple syrup. The compound sotolone, a metabolite of leucine, is responsible for this smell.
−
BCAAs and alpha-keto acid concentrations in blood plasma are increased which has toxic effects like ketonuria, lethargy, seizures, vomiting, problems in feeding and neurological dysfunctions. As a consequence of this, if untreated the disease leads to coma and in the end to death.
 +
[http://en.wikipedia.org/wiki/Branched-chain_amino_acid BCAAs] and α-keto acid concentrations in blood plasma are increased, which has toxic effects like ketonuria, lethargy, seizures, vomiting, problems in feeding and neurological dysfunctions. As a consequence of this, if untreated, the disease leads to coma and in the end to death.
   
−
There are different forms of MSUD depending on the proportion of BCKDC enzyme activity that is still present:
 +
There are different forms of MSUD, depending on the proportion of [http://en.wikipedia.org/wiki/Branched-chain_alpha-keto_acid_dehydrogenase_complex BCKDC] enzyme activity that is still present:
−
* The ''classic severe'' neonatale form is the most common form where almost no rest enzyme activity can be measured. The newborns develop severe symptoms 4 to 7 days after birth.
 +
* The ''classic severe'' neonatale form is the most common form, where almost no remaining enzyme activity can be measured. The newborns develop severe symptoms 4 to 7 days after birth.
 
* In the ''intermediate'' form there is an enzyme activity of up to 30 %. So the symptoms are less severe than in the classic form.
  
* In the ''intermediate'' form there is an enzyme activity of up to 30 %. So the symptoms are less severe than in the classic form.
−
* The ''intermittend'' form has a later onset because there is a partial enzyme activity. Symptoms can appear episodically. A dietary restriction with low BCAA content can be an effective treatment.
 +
* The ''intermittend'' form has a later onset, because there is only a partial enzyme activity. Symptoms can appear episodically. A dietary restriction with low BCAA content can be an effective treatment.
−
* In the ''thiamine-responsive'' form there is an enzyme activity of up to 40 %. The serum levels of BCAAs can be normalized with a thiamine therapy because in this form a mutation affects the affinity of a thiamine binding site of the BCKDC.
 +
* In the ''thiamine-responsive'' form there is an enzyme activity of up to 40 %. The serum levels of BCAAs can be normalized with a thiamine therapy, because in this form a mutation affects the affinity of a thiamine binding site of the BCKDC.
 
All of the above mentioned forms can be caused by mutations in the gene of any subunit of the BCKDC.
 
All of the above mentioned forms can be caused by mutations in the gene of any subunit of the BCKDC.
   
−
Another classification divides the disease into subtypes depending on the subunit of the enzyme complex (see [[#Biochemical disease mechanism]]) that is altered - type IA/IB/II or III if subunit E1 (alpha chain), E1 (beta chain), E2 or E3 is altered, respectively. In some sources type III is actually considered another disease which is similar to MSUD, called dihydroliponamide dehydrogenase deficiency. The reason is that this subunit is also a part of other enzyme complexes, e. g. the pyruvate dehydrogenase complex.
 +
Another classification divides the disease into subtypes depending on the subunit of the enzyme complex (see [[#Biochemical disease mechanism|Biochemical disease mechanism]]) that is altered - type IA/IB/II or III if subunit E1 (α chain), E1 (β chain), E2 or E3 is altered, respectively. In some sources type III is actually considered another disease, which is similar to MSUD, called dihydroliponamide dehydrogenase deficiency. The reason is that this subunit is also a part of other enzyme complexes, e. g. the pyruvate dehydrogenase complex.
   
 
=== Cross-references ===
 
=== Cross-references ===
Line 32: Line 34:
   
 
<!-- Introduction to pathway -->
  
<!-- Introduction to pathway -->
−
The first step in degradation of the BCAAs leucine, isoleucine and valine is the oxidation to branched chain alpha-keto acids (BCKAs). This reaction is catalyzed by '''cytosolic branched-chain amino-acid aminotransferase''' which cuts off the &alpha;-amino group of the BCAAs and substitutes the chemical group with a carbonyl group. This process takes part in the cytosol of cells. The produced &alpha;-keto acids are then transported into mitochondria and decarboxylated by the BCKDC. After a chain of reactions in mitochondria branched-chain &alpha;-keto acids will be transformed to derives of CoA, e.g. Acetyl-CoA and Succinyl-CoA, which can participate into other metabolic pathways such as citrate cycle. If the function of the enzyme complex BCKDC is disturbed like in MSUD, the amino acids and their metabolites (BCKAs) can't be removed and accumulate in blood and tissue. Accumulation of BCKAs results in a ketoacidose, i. e. the pH value of the blood decreases, which explains some of the symptoms described in [[#Phenotype]].
 +
The first step in degradation of the BCAAs leucine, isoleucine and valine is the oxidation to branched chain &alpha;-keto acids (BCKAs). This reaction is catalyzed by [http://en.wikipedia.org/wiki/Branched_chain_aminotransferase '''cytosolic branched-chain amino-acid aminotransferase'''] which cuts off the &alpha;-amino group of the BCAAs and substitutes the chemical group with a carbonyl group. This process takes part in the cytosol of cells. The produced &alpha;-keto acids are then transported into mitochondria and decarboxylated by the BCKDC. After a chain of reactions in mitochondria branched-chain &alpha;-keto acids will be transformed to derivatives of CoA, e.g. Acetyl-CoA and Succinyl-CoA, which can participate in other metabolic pathways such as the citrate cycle.
  +
  +
If the function of the enzyme complex BCKDC is disturbed like in MSUD, the amino acids and their metabolites (BCKAs) cannot be removed and accumulate in blood and tissue. Accumulation of BCKAs results in a ketoacidose, i. e. the pH value of the blood decreases, which explains some of the symptoms described in [[#Phenotype|Phenotype]].
  +
  +
Because of the accumulation of leucine in the brain, other essential amino acids are displaced, which leads to depletion of important neurotransmitters like glutamate. Also the energy metabolism is disturbed, since the accumulation of BCKAs interrupts the citric acid cycle.
   
 
<!-- Introduction of enzyme complex -->
  
<!-- Introduction of enzyme complex -->
−
=== Branched-chain &alpha;-keto acids dehydrogenase complex ===
 +
=== Branched-chain &alpha;-keto acid dehydrogenase complex ===
 
<!-- Introduction of enzyme complex -->
  
<!-- Introduction of enzyme complex -->
−
The branched-chain &alpha;-keto acids dehydrogenase complex (BCKDC) is the main catalysator for the degradation of BCAAs in mitochondrial matrix. It has three component enzymes with different catalytic activities (genes are given in braces):
 +
The mitochondrial branched-chain &alpha;-keto acid dehydrogenase complex (BCKDC) is the main catalysator for the degradation of BCAAs in mitochondrial matrix. It has three component enzymes with different catalytic activities:
 
<!-- Introduction of component enzymes -->
  
<!-- Introduction of component enzymes -->
  +
* component E1: The E1 subunit is the branched-chain &alpha;-keto acid dehydrogenase. It catalyzes the decarboxylation of &alpha;-keto acids and triggers the activity of E2 subunit by means of catalyzing binding between E2 subunit and its cofactor. The component E1 has two polypeptide subunits: the &alpha; unit [[BCKDHA]] and the &beta; unit [[BCKDHB]].
−
* E1: alpha-keto acid dehydrogenase (alpha chain [http://en.wikipedia.org/wiki/BCKDHA BCKDHA], beta chain [http://en.wikipedia.org/wiki/BCKDHB BCKDHB])
  
  +
−
* E2: dihydrolipoyl transacylase ([http://en.wikipedia.org/wiki/DBT_%28gene%29 DBT])
  
  +
* component E2: dihydrolipoyl transacylase ([[DBT]])
−
* E3: dyhydroliponamide dehydrogenase ([http://en.wikipedia.org/wiki/Dihydrolipoamide_dehydrogenase DLD])
  
  +
* component E3: dyhydroliponamide dehydrogenase ([[DLD]])
   
 
=== Cross-references ===
  
=== Cross-references ===
Line 50: Line 57:
   
 
== Genetics of MSUD ==
  
== Genetics of MSUD ==
−
The maple syrup urine disease can be inherited between generations. It follows a recessive manner of inheritance.
+
The maple syrup urine disease can be inherited between generations. It follows a recessive manner of inheritance. All the genes which encode component enzymes of BCDKC are located on autosomes. The MSUD is then an [http://en.wikipedia.org/wiki/Autosomal_recessive#Autosomal_recessive_gene autosomal recessive disease] in which only individuals who are homozygous or compound heterozygous for the mutated allel of the same enzyme subunit develop the disease. MSUD shows higher prevalence in some ethnic groups e.g. Mennonite and Jews.
  +
 
=== Mutations ===
  
=== Mutations ===
 
For each of the four genes BCKDHA, BCKDHB, DBT and DLD that produce subunits of BCKDC mutations are found among the population.
 
For each of the four genes BCKDHA, BCKDHB, DBT and DLD that produce subunits of BCKDC mutations are found among the population.
Line 75: Line 83:
 
==== Reference sequence ====
  
==== Reference sequence ====
   
−
Which sequence does not cause the disease and is most often found in the population.
+
The following sequences do not cause the disease and are most often found in the population.
   
 
* [[BCKDHA#Reference_sequence|Reference sequence of BCKDHA]]
  
* [[BCKDHA#Reference_sequence|Reference sequence of BCKDHA]]
Line 93: Line 101:
 
==== Disease causing mutations ====
  
==== Disease causing mutations ====
   
−
Following mutations in the corresponding gene can result into functional changes of BCKDC and thus lead to MSUD.
 +
Following mutations in the corresponding gene can result in functional changes of BCKDC and thus lead to MSUD.
   
 
* [[BCKDHA#Disease_causing_mutations|Disease causing mutations in BCKDHA]]
  
* [[BCKDHA#Disease_causing_mutations|Disease causing mutations in BCKDHA]]
Line 101: Line 109:
   
 
== Diagnosis ==
  
== Diagnosis ==
−
For a diagnosis of MSUD at first the above mentioned symptoms have to be present. The enzyme activity of the BCKDC can be measured and compared to the normal activity. With HPLC or mass spectrometry the accumulation of BCAAs, allo-isoleucine and BCKAs in the plasma can be measured. BCKAs in the urine are detected with dinitrophenylhydrazine ([http://en.wikipedia.org/wiki/DNPH DNPH]), which forms a precipitate with these compounds. To confirm the diagnosis, the genes encoding BCKDC subunits can be sequenced for mutations.
 +
For a diagnosis of MSUD, at first the above mentioned symptoms have to be present. The enzyme activity of the BCKDC can be measured and compared to the normal activity. With HPLC or mass spectrometry the accumulation of BCAAs, allo-isoleucine and BCKAs in the plasma can be measured. BCKAs in the urine are detected with dinitrophenylhydrazine ([http://en.wikipedia.org/wiki/DNPH DNPH]), which forms a precipitate with these compounds. To confirm the diagnosis, the genes encoding BCKDC subunits can be genetically tested for mutations.
   
 
== Treatment ==
  
== Treatment ==
−
To normalize the levels of amino acids and alpha-keto acids a special, almost protein free, diet with low levels of BCAAs is given. To avoid deficits in other nutrients there exist formulas for MSUD which are free of BCAAs. The blood of affected patients is frequently tested and BCAA concentrations are carefully monitored so that the brain is not damaged.
 +
To normalize the levels of amino acids and &alpha;-keto acids a special, almost protein free, diet with low levels of BCAAs is given. To avoid deficits in other nutrients, there exist formulas for MSUD which are free of BCAAs. The blood of affected patients is frequently tested and BCAA concentrations are carefully monitored so that the brain is not damaged.
  +
  +
To reduce too high serum levels of BCAA, also a hemodialysis can be carried out. Liver transplantation is a treatment that helps to normalize the degradation of BCKAs. Finally there is a clinical trail, that investigates the benefit of the compound phenylbutyrate, which reduces the blood levels of BCAAs and BCKAs.
  +
  +
== Tasks ==
  +
* [[Task 2 (MSUD)|Task 2: Sequence Alignment]]
  +
* [[Task 3 (MSUD)|Task 3: Sequence-based Prediction]]
  +
* [[Task 4 (MSUD)|Task 4: Structural Alignments]]
  +
* [[Task 5 (MSUD)|Task 5: Homology Modelling]]
  +
* [[Task 6 (MSUD)|Task 6: Structural Modelling using Evolutionary Sequence Variation]]
  +
* [[Task 7 (MSUD)|Task 7: Researching SNPs]]
  +
* [[Task 8 (MSUD)|Task 8: Sequence-based mutation analysis]]
  +
* [[Task 9 (MSUD)|Task 9: Structure-based mutation analysis]]
  +
* [[Task 10 (MSUD)|Task 10: Normal Mode Analysis]]
   
 
== References ==
  
== References ==
Line 117: Line 138:
 
http://www.genome.jp/kegg/disease/ <br>
  
http://www.genome.jp/kegg/disease/ <br>
 
http://metacyc.org/ <br>
  
http://metacyc.org/ <br>
  +
http://health.nytimes.com/health/guides/disease/maple-syrup-urine-disease/overview.html <br>
  +
http://clinicaltrials.gov/show/NCT01529060 <br>
  +
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2668944/ <br>
  +
http://www.jci.org/articles/view/67217

Latest revision as of 14:18, 23 July 2013

Crystal structure of the human mitochondrial branched-chain α-ketoacid dehydrogenase, subunit E1 (source: http://www.pdb.org/, pdb-id 1U5B)

Summary

Maple syrup urine disease (MSUD) is a disorder of the branched chain amino acid (BCAA) catabolism. Due to a deficiency in the branched chain α-keto acid dehydrogenase complex (BCKDC) the degradation of leucine, isoleucine and valine is impaired so that these amino acids and the corresponding α-keto acids accumulate. Affected infants suffer from mental and physical retardation. MSUD has an autosomal recessive heredity.

The slides of the introductory talk can be found here: MSUD presentation

Phenotype

Sotolone (source: http://www.ebi.ac.uk/chebi/)

The name of the disease comes from the sweet smell of newbornes urine that resembles maple syrup. The compound sotolone, a metabolite of leucine, is responsible for this smell. BCAAs and α-keto acid concentrations in blood plasma are increased, which has toxic effects like ketonuria, lethargy, seizures, vomiting, problems in feeding and neurological dysfunctions. As a consequence of this, if untreated, the disease leads to coma and in the end to death.

There are different forms of MSUD, depending on the proportion of BCKDC enzyme activity that is still present:

  • The classic severe neonatale form is the most common form, where almost no remaining enzyme activity can be measured. The newborns develop severe symptoms 4 to 7 days after birth.
  • In the intermediate form there is an enzyme activity of up to 30 %. So the symptoms are less severe than in the classic form.
  • The intermittend form has a later onset, because there is only a partial enzyme activity. Symptoms can appear episodically. A dietary restriction with low BCAA content can be an effective treatment.
  • In the thiamine-responsive form there is an enzyme activity of up to 40 %. The serum levels of BCAAs can be normalized with a thiamine therapy, because in this form a mutation affects the affinity of a thiamine binding site of the BCKDC.

All of the above mentioned forms can be caused by mutations in the gene of any subunit of the BCKDC.

Another classification divides the disease into subtypes depending on the subunit of the enzyme complex (see Biochemical disease mechanism) that is altered - type IA/IB/II or III if subunit E1 (α chain), E1 (β chain), E2 or E3 is altered, respectively. In some sources type III is actually considered another disease, which is similar to MSUD, called dihydroliponamide dehydrogenase deficiency. The reason is that this subunit is also a part of other enzyme complexes, e. g. the pyruvate dehydrogenase complex.

Cross-references

See also description of this disease in

Biochemical disease mechanism

The branched chain amino acids leucine, isoleucine and valine (source: http://www.ebi.ac.uk/chebi/)
BCAA degradation (source: KEGG) highlighting disease associated enzymes

The first step in degradation of the BCAAs leucine, isoleucine and valine is the oxidation to branched chain α-keto acids (BCKAs). This reaction is catalyzed by cytosolic branched-chain amino-acid aminotransferase which cuts off the α-amino group of the BCAAs and substitutes the chemical group with a carbonyl group. This process takes part in the cytosol of cells. The produced α-keto acids are then transported into mitochondria and decarboxylated by the BCKDC. After a chain of reactions in mitochondria branched-chain α-keto acids will be transformed to derivatives of CoA, e.g. Acetyl-CoA and Succinyl-CoA, which can participate in other metabolic pathways such as the citrate cycle.

If the function of the enzyme complex BCKDC is disturbed like in MSUD, the amino acids and their metabolites (BCKAs) cannot be removed and accumulate in blood and tissue. Accumulation of BCKAs results in a ketoacidose, i. e. the pH value of the blood decreases, which explains some of the symptoms described in Phenotype.

Because of the accumulation of leucine in the brain, other essential amino acids are displaced, which leads to depletion of important neurotransmitters like glutamate. Also the energy metabolism is disturbed, since the accumulation of BCKAs interrupts the citric acid cycle.

Branched-chain α-keto acid dehydrogenase complex

The mitochondrial branched-chain α-keto acid dehydrogenase complex (BCKDC) is the main catalysator for the degradation of BCAAs in mitochondrial matrix. It has three component enzymes with different catalytic activities:

  • component E1: The E1 subunit is the branched-chain α-keto acid dehydrogenase. It catalyzes the decarboxylation of α-keto acids and triggers the activity of E2 subunit by means of catalyzing binding between E2 subunit and its cofactor. The component E1 has two polypeptide subunits: the α unit BCKDHA and the β unit BCKDHB.
  • component E2: dihydrolipoyl transacylase (DBT)
  • component E3: dyhydroliponamide dehydrogenase (DLD)

Cross-references

Genetics of MSUD

The maple syrup urine disease can be inherited between generations. It follows a recessive manner of inheritance. All the genes which encode component enzymes of BCDKC are located on autosomes. The MSUD is then an autosomal recessive disease in which only individuals who are homozygous or compound heterozygous for the mutated allel of the same enzyme subunit develop the disease. MSUD shows higher prevalence in some ethnic groups e.g. Mennonite and Jews.

Mutations

For each of the four genes BCKDHA, BCKDHB, DBT and DLD that produce subunits of BCKDC mutations are found among the population.

Reported mutations according to HGMD
Gene Mutations
BCKDHA 65
BCKDHB 65
DBT 53
DLD 17


Reference sequence

The following sequences do not cause the disease and are most often found in the population.

Neutral mutations

These reported mutations are neutral and do not alter the protein during translation.

Disease causing mutations

Following mutations in the corresponding gene can result in functional changes of BCKDC and thus lead to MSUD.

Diagnosis

For a diagnosis of MSUD, at first the above mentioned symptoms have to be present. The enzyme activity of the BCKDC can be measured and compared to the normal activity. With HPLC or mass spectrometry the accumulation of BCAAs, allo-isoleucine and BCKAs in the plasma can be measured. BCKAs in the urine are detected with dinitrophenylhydrazine (DNPH), which forms a precipitate with these compounds. To confirm the diagnosis, the genes encoding BCKDC subunits can be genetically tested for mutations.

Treatment

To normalize the levels of amino acids and α-keto acids a special, almost protein free, diet with low levels of BCAAs is given. To avoid deficits in other nutrients, there exist formulas for MSUD which are free of BCAAs. The blood of affected patients is frequently tested and BCAA concentrations are carefully monitored so that the brain is not damaged.

To reduce too high serum levels of BCAA, also a hemodialysis can be carried out. Liver transplantation is a treatment that helps to normalize the degradation of BCKAs. Finally there is a clinical trail, that investigates the benefit of the compound phenylbutyrate, which reduces the blood levels of BCAAs and BCKAs.

Tasks

References

http://en.wikipedia.org/wiki/Maple_syrup_urine_disease
http://de.wikipedia.org/wiki/Ahornsirupkrankheit
http://www.pdb.org/
http://www.omim.org/entry/248600
http://www.hgmd.cf.ac.uk/ac/index.php
http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001411/
http://www.ncbi.nlm.nih.gov/books/NBK1319/
http://www.ebi.ac.uk/chebi
http://www.genome.jp/kegg/disease/
http://metacyc.org/
http://health.nytimes.com/health/guides/disease/maple-syrup-urine-disease/overview.html
http://clinicaltrials.gov/show/NCT01529060
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2668944/
http://www.jci.org/articles/view/67217

Retrieved from "https://i12r-studfilesrv.informatik.tu-muenchen.de/wiki/index.php?title=Maple_Syrup_Urine_Disease&oldid=33530"